|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||76.36 - 77.70|
|52 Week Range||64.27 - 89.54|
|PE Ratio (TTM)||29.43|
|Earnings Date||Jul 25, 2018|
|Forward Dividend & Yield||2.28 (3.03%)|
|1y Target Est||86.00|
Yahoo Finance’s Seana Smith and Jared Blikre with up-to-the-minute market analysis and the biggest headlines in midday trading Tuesday.
The SG&A expenses incurred by Stryker (SYK) are expected to increase 9.4% from $1.05 billion in the second quarter of 2017 to $1.15 billion in the second quarter. Total operating expenses incurred by Stryker are expected to reach $1.42 billion for the second quarter, compared with $1.49 billion for the second quarter of 2017. Analysts expect Stryker (SYK) to report net income of $549.25 million in the second quarter compared with $391.0 million in the second quarter of 2017, an increase of 40.47%.
Gilead Sciences’ (GILD) selling, general, and administrative expenses are expected to increase 10.87%, from $827 million in Q2 2017 to $916.87 million in Q2 2018. Its research and development expenses are expected to increase 8.78%, from $812 million in Q2 2017 to $883.27 million in Q2 2018. Its expenses on stock-based compensation are expected to rise from $61 million in Q2 2017 to $194.33 million in Q2 2018.
Gilead Sciences (GILD) is expected to report its second-quarter earnings on July 25. Analysts expect Gilead Sciences’ revenues to decline 27.18%, from $7.14 billion in Q2 2017 to $5.2 billion in Q2 2018. In Q2 2017, its revenues shrunk 8.17%.
Gilead Sciences Inc. (GILD) said early Thursday that its Kite unit will partner with privately-held Gadeta B.V. to develop new cancer therapies called gamma delta T cell receptor therapies. Gadeta's proprietary technology in this area, which is a type of cell therapy, may be used to treat blood cancers and solid tumors. Kite will fund the research and development costs and buy equity in Gadeta, with the "exclusive option" to acquire Gadeta.
Kite, a Gilead Company (GILD), and Gadeta B.V., a privately-held company focused on the discovery and development of novel cancer immunotherapies based on gamma delta T cell receptors (TCRs), have entered into a strategic collaboration to develop novel gamma delta TCR therapies in various cancers. Under the financial terms, Kite will provide research and development (R&D) funding for the collaboration and Gadeta will be eligible to receive future payments upon achievement of certain regulatory milestones.
Jim Cramer and technician Bob Lang inspect the charts to see if big-cap biotechnology stocks like Gilead and Celgene could have more room to run.
Who has the most productive workforce in the Bay Area, and how much does each employee rake in per year, on average?
The next big market for biopharma could be nonalcoholic steatohepatitis, so upcoming data from these companies could be market-moving.
Gilead Sciences, Inc. (GILD) announced today that its second quarter 2018 financial results will be released on Wednesday, July 25, after the market closes. At 5:00 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the second quarter 2018 and provide a general business update. Alternatively, please call 1-877-359-9508 (U.S.) or 1-224-357-2393 (international) and dial the conference ID 8988927 to access the call.
Gilead Sciences Inc. ( GILD) stock may be finally starting to show a revival after three years of sharp declines, dragging the stock down by over 30%. Options traders are betting the rally in Gilead will continue as well, and they see the stock rising to about $82 by the middle of August. The longer-term outlook for Gilead still proves to be questionable with the company still facing declining revenues as it rebuilds its drug pipeline.
Celgene Corporation (NASDAQ:CELG) stock looks attractive here, for a number of reasons. Celgene stock has sold off, losing about 43% of its value. Celgene touched a four-year low in May before a recent rebound. The decline leaves Celgene looking awfully cheap, at a little over 8.3x 2019 consensus EPS estimates.
Biotech is a notoriously risky business. Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Of course, when a biotech product succeeds, investors can make a lot of money.
The following four stocks are currently in the midst of uptrends according to VantagePoint, an AI charting platform that uses intermarket analysis and artificial intelligence to predict future price action 1-3 days in advance. The blue line is a predicted moving average that forecasts a stock's moving average two days out. Ford Motor Company (NYSE: F) was on a clear downtrend starting on June 13, but that looks to have ended for now as the stock has bounced off the $11 level.